Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Induction and Response-Stratified CRT in HPV-Negative Head and Neck Cancer
NCT03944915Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Aug 2019
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by University of Chicago. Primary endpoint: Deep Response Rate at 2 years. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03944915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944915.